At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
Semaglutidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jan 2, 2020·Updated Oct 1, 2024
In Brief
A Phase 2 clinical trial evaluating Semaglutide for HIV Infections and Non-Alcoholic Fatty Liver Disease. Completed, enrolled 51 participants across 9 sites in 2 countries.
Detailed Summary
The purpose of this study was to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Non-Alcoholic Fatty Liver Disease
CountriesBrazil, United States
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartFeb 2021
Primary CompletionMar 2023
Study CompletionSep 2023
TodayJul 2026
First PostedJan 2, 2020
Enrollment StartFeb 19, 2021
Primary CompletionMar 16, 2023
Study CompletionSep 15, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.5 years ago
Interventions
Semaglutidedrug
Administered subcutaneously